

EUROPEAN LUNG CANCER CONFERENCE 2016

ANY ROLE OF PROPHYLACTIC CRANIAL IRRADIATION IN NSCLC

Cecile Le Pechoux

Department of Radiation Oncology








elcc2016.org


DISCLOSURE SLIDE


No disclosures to declare



Brain: Frequent site of failure in SCLC and NSCLC but BM are less frequent in NSCLC than SCLC,







Steeg Nature Reviews | Cancer


2011

NSCLC

Risk of BM: 15 to 40% as 1st site of recurrence, but 10 to 54% overall Higher rate in

- adenocarcinoma
- Higher stage
- Nodal involvement





PCI or no PCI ? in high risk NSCLC patients

Author	Patients	Stage	Dose N fr	BM No PCI	BM PCI	р	OS No PCI	OS PCI	р
Cox 1981 VALG	281	inoperable	20/10	13%	6%	0.038	41.4 wks	35.4 wks	0.5
Umsawasdi 1984	97	I, II or III	30/10	27%	4%	0.002	-	-	-
Russel 1991 RTOG	187	11/111	30/10	19%	9%	0.1	2-yr SR 21%	2-yr SR 13%	0.36
	26	Resected Pts		25%	0%	0.06			
	161	Inop		18%	10%	0.34			


- ✤ Old trials!! No imaging ...
- As systemic extra-cerebral control has improved, higher rate of BM
- Need for trials to reconsider PCI in NSCLC

RISK FACTORS OF DEVELOPMENT OF BM

- Outside of histology (adenocarcinoma), and stage (Stage III)
- Other factors have been described
- Age : Younger age or older
- Gender
- Response to treatment :
 - Good responders after Neo adjuvant CT or Neoadjuvant CTRT
 - Persistent nodal involvement after neoadjuvant treatment
- Superior sulcus location
- Genotype (patients with ALK rearrangement, EGFR mutation at higher risk)



Role of PCI in stage III treated with 3modality



- Seventy-five patients : first 28 pts had no PCI, then following 47 pts were administered PCI (30 Gy/15 fr)
- PCI reduced the rate of BM as first site of relapse from 30% to 8% at 4 years (P=0.005) and that of overall brain relapse from 54% to 13% (P < .0001).
- Neuropsychologic testing : impairments in attention and visual memory in long-term survivors whether they received or not PCI



Evidence in favour of PCI in NSCLC?

VOLUME 25 · NUMBER 31 · NOVEMBER 1 2007

JOURNAL OF CLINICAL ONCOLOGY


ORIGINAL REPORT

Prophylactic Cranial Irradiation in Operable Stage IIIA Non–Small-Cell Lung Cancer Treated With Neoadjuvant Chemoradiotherapy: Results From a German Multicenter Randomized Trial

Christoph Pöttgen, Wilfried Eberhardt, Andreas Grannass, Soenke Korfee, Georg Stüben, Helmut Teschler, Georgios Stamatis, Horst Wagner, Bernward Passlick, Volker Petersen, Volker Budach, Hans Wilhelm, Isabel Wanke, Herbert Hirche, Hans-Jochen Wilke, and Martin Stuschke



SCHEMA Essen Trial Pottgen et al, JCO 07



Brain relapse as 1st site of failure in stage III resected patients




Fig 1. Actuarial probabilities of brain relapse at first site of failure by intent-totreat analysis.

No PCI Actuarial Probability of PCI 0.4 **Brain Relapse** 0.3 0.2 0.1 60 72 84 108 0 12 24 36 48 96 Time (months) No. patients at risk 62 15 10 3 43 12 8 1

0.5


Fig 2. Actuarial probabilities of brain relapse at first site of failure according to the treatment actually administered. PCI, prophylactic cranial irradiation.

	Surg + TRT, No PCI		CTRTSurg +PCI	
2 yr Rate BM	23,7% ITA	22,8%	8,8%	7,8%
5 yr Rate BM	30,7% ITA	34,7%	15,8%	7,8%

Pottgen et al, JCO 2007




Schema of RTOG 0214



340 pts analysed / 1058 needed to show a survival improval Primary objective: survival
 S^{ary} objectives: BM, DFS,QoL, Neuropsychological Function
 Core et al, JCO 2010

RTOG 0214: PCI vs no PCI in NSCLC



5 yr update will soon be published: it shows

- decreased rate of BM
- improved DFS, but no effect on OS



Phase III Trial evalutating PCI in Locally Advanced NSCLC: Neurocognitive and Quality-of-Life Analysis.

340 pts analysed

Sun et al, JCO 2011

Prophylactic Cranial Irradiation	Observation	
No significant differences at 1 year in		
Mini mental Status Examination MMSE (P <0	.60) or	
Activities of Daily Leaving scale ADLS (P <0.8	88).	

		P	CI			Obser	vation			
Greater o	lecline	ofme	mory	(HVLT) in th	e PCI	arm at	t 1 yea	r	
Immediat	e reca	ll (P <	0 .03)							
Delayed	recall ((P < .0	(80							
D. L. L. H	8	15	44	85	8	14	50	86	.81	.81
Delayed recall										

Trials evaluating PCI in resected St III NSCLC


- 156 patients (81 to PCI group and 75 to control group).
 DFS PCI group > control group
 - median DFS of 28.5 mo vs 21.2 mo [HR 0.67; P= 0.037]
- Decrease in risk of brain metastases

Li et al, Ann Onc 2015

- ◆ 5-year BM rate, 20.3% versus 49.9%; HR, 0.28; P < 0.001).</p>
- No difference in Median OS
 - 31.2 months in the PCI group and 27.4 months in the control group (HR, 0.81; 95% CI 0.56-1.16; P = 0.310).



Trials evaluating PCI in resected St III



CANCER CONFERENCE 2016






Figure 2. Results of the meta-analysis on studies evaluating the effect of PCI on brain metastases: OR: 0.30 (95% CI: 0.21-0.43).





SEER Data base study 17852 Stage III **NSCLC** pts diagnosed 1988-1997 326 pts (1,8%) had PCI No difference in OS No difference in subgroups of pts at higher risk

Park, Clin Lung Cancer 2015




elcc

Potential toxicity of PCI to be discussed with pts



Beneficial effects of PCI on survival and incidence of BM.




Deterioration generally mild, of cognitive functions



Rationale of hippocampus sparing to reduce possible neurotoxicity

- Hippocampus primarily involved in the consolidation of new memories and "good humour".
- Contains neural stem cells involved in the repair of damage to the CNS
- Hippocampal involvement by metastatic disease is rare in NSCLC (5-12%)
- Hippocampus sparing may result in lower rates of memory loss to be evaluated in PCI prospective trials with close follow-up++ in terms of BM
- Phase II trial showed less NC decline/historical series
- Ongoing trials

Monje Nat Med 2002; Marsh et al, 2010; Gondi, Rad&Oncol 2010; Ghia IJROBP 2007; Guttierez IJROBP 2007; Gondi et al 2014



Trials in PDQ ClinicalTrials.gov

NCT01282437 Netherland	Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC (NVALT11) completed trial
NCT00745797 China	Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy (PCI) Closed because of slow accrual
NCT02448992 China	Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer ?
NCT01158170 China	Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001) ?
NCT01603849 Mexico	Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis (PCI) ?
NCT00955695 Korea	A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib ?
NCT02341170 Germany	A Phase III Trial of Hippocampal-sparing Prophylactic Cranial Irradiation (HS-PCI) in Locally Advanced (Stage IIIA/IIIB) Adenocarcinoma of the Lung (not yet started, 438 pts planned)

Conclusion

- PCI reduces the incidence of BM (18% at 1 yr vs 8%)
- No effect on survival:
- Updated results are awaited from RTOG 0214
- PCI in NSCLC is not recommended
- New MA?? With new generation of randomized trials...
- Hippocampus sparing PCI may contribute to reduce neurotoxicity

